GlassScriptPhysician profile
Brian K Jefferson
NPI 1508830407
$546,527.04
in general payments reported to CMS, 2019-2025
42 companies · $94K in 2025
The $94K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $26K · 2021: $27K · 2022: $110K · 2023: $105K · 2024: $130K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $95K · Consulting Fee: $59K · Food and Beverage: $32K · Travel and Lodging: $28K · Grant: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,450.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $95,250.00 |
| Consulting Fee | $59,425.00 |
| Food and Beverage | $31,988.80 |
| Travel and Lodging | $28,369.29 |
| Grant | $222.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $255,701.62 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Boston Scientific Corporation | $187,703.27 | 2019-2025 | General - Vascular Access, General - Balloon Catheters, Avvigo Guidance System |
| Cardiovascular Systems INC. | $27,306.22 | 2019-2022 | |
| Medtronic, INC. | $26,218.29 | 2021-2025 | Symplicity G3, Onyx Frontier, Resolute Onyx |
| Abbott Laboratories | $17,261.96 | 2019-2024 | Diamondback Coronary, Esprit, Hi-Torque Balance |
| Abiomed | $7,610.83 | 2019-2024 | Impella |
| Asahi Intecc USA, INC. | $5,650.05 | 2019-2024 | Peripheral Vascular |
| Teleflex LLC | $5,395.53 | 2019-2023 | Guideliner, Trapliner, Turnpike |
| Penumbra, INC. | $3,511.36 | 2021-2024 | Indigo System |
| Procyrion, INC. | $2,925.00 | 2024-2025 | Aortix System |
| Arrow International, INC. | $2,015.45 | 2019 | |
| Medtronic Vascular, INC. | $1,615.82 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $750.00 | 2024 | |
| Inari Medical, INC. | $661.33 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Spectrawave, INC | $227.43 | 2025 | Starlight Imaging Catheter, Hypervue Imaging System |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jefferson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.